These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
538 related articles for article (PubMed ID: 27593158)
1. Development and approval of live attenuated influenza vaccines based on Russian master donor viruses: Process challenges and success stories. Rudenko L; Yeolekar L; Kiseleva I; Isakova-Sivak I Vaccine; 2016 Oct; 34(45):5436-5441. PubMed ID: 27593158 [TBL] [Abstract][Full Text] [Related]
2. Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries. Rudenko L; van den Bosch H; Kiseleva I; Mironov A; Naikhin A; Larionova N; Bushmenkov D Vaccine; 2011 Jul; 29 Suppl 1():A40-4. PubMed ID: 21684428 [TBL] [Abstract][Full Text] [Related]
3. Safety, immunogenicity and infectivity of new live attenuated influenza vaccines. Isakova-Sivak I; Rudenko L Expert Rev Vaccines; 2015; 14(10):1313-29. PubMed ID: 26289975 [TBL] [Abstract][Full Text] [Related]
4. Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus. Rudenko L; Isakova-Sivak I Expert Rev Vaccines; 2015 Mar; 14(3):395-412. PubMed ID: 25555687 [TBL] [Abstract][Full Text] [Related]
5. Genetic stability of live attenuated vaccines against potentially pandemic influenza viruses. Kiseleva I; Dubrovina I; Fedorova E; Larionova N; Isakova-Sivak I; Bazhenova E; Pisareva M; Kuznetsova V; Flores J; Rudenko L Vaccine; 2015 Dec; 33(49):7008-14. PubMed ID: 26432909 [TBL] [Abstract][Full Text] [Related]
6. Development of influenza vaccine production capacity by the Government Pharmaceutical Organization of Thailand: addressing the threat of an influenza pandemic. Surichan S; Wirachwong P; Supachaturas W; Utid K; Theerasurakarn S; Langsanam P; Lakornrach P; Nitisaporn L; Chansikkakorn C; Vangkanonta W; Kaweepornpoj R; Poopipatpol K; Thirapakpoomanunt S; Srichainak S; Artavatkun W; Chokevivat V; Wibulpolprasert S Vaccine; 2011 Jul; 29 Suppl 1():A29-33. PubMed ID: 21684425 [TBL] [Abstract][Full Text] [Related]
7. Novel Approaches for The Development of Live Attenuated Influenza Vaccines. Blanco-Lobo P; Nogales A; RodrÃguez L; MartÃnez-Sobrido L Viruses; 2019 Feb; 11(2):. PubMed ID: 30813325 [TBL] [Abstract][Full Text] [Related]
8. A pandemic influenza vaccine in India: from strain to sale within 12 months. Dhere R; Yeolekar L; Kulkarni P; Menon R; Vaidya V; Ganguly M; Tyagi P; Barde P; Jadhav S Vaccine; 2011 Jul; 29 Suppl 1():A16-21. PubMed ID: 21684421 [TBL] [Abstract][Full Text] [Related]
9. Development of live attenuated influenza vaccines against pandemic influenza strains. Coelingh KL; Luke CJ; Jin H; Talaat KR Expert Rev Vaccines; 2014 Jul; 13(7):855-71. PubMed ID: 24867587 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Osterholm MT; Kelley NS; Sommer A; Belongia EA Lancet Infect Dis; 2012 Jan; 12(1):36-44. PubMed ID: 22032844 [TBL] [Abstract][Full Text] [Related]
11. Chemistry, manufacturing and control (CMC) and clinical trial technical support for influenza vaccine manufacturers. Wahid R; Holt R; Hjorth R; Berlanda Scorza F Vaccine; 2016 Oct; 34(45):5430-5435. PubMed ID: 27484011 [TBL] [Abstract][Full Text] [Related]
12. A review of epidemic preparedness for influenza through local vaccine production: national security for Thailand. Pitisuttithum P; Wirachwong P Hum Vaccin Immunother; 2019; 15(10):2440-2445. PubMed ID: 31335234 [TBL] [Abstract][Full Text] [Related]
13. Advancing new vaccines against pandemic influenza in low-resource countries. Berlanda Scorza F Vaccine; 2017 Sep; 35(40):5397-5402. PubMed ID: 28410815 [TBL] [Abstract][Full Text] [Related]
14. Live attenuated vaccines for pandemic influenza. Chen GL; Subbarao K Curr Top Microbiol Immunol; 2009; 333():109-32. PubMed ID: 19768402 [TBL] [Abstract][Full Text] [Related]
15. Production of live attenuated influenza vaccines against seasonal and potential pandemic influenza viruses. Jin H; Chen Z Curr Opin Virol; 2014 Jun; 6():34-9. PubMed ID: 24705137 [TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. Carr S; Allison KJ; Van De Velde LA; Zhang K; English EY; Iverson A; Daw NC; Howard SC; Navid F; Rodriguez-Galindo C; Yang J; Adderson EE; McCullers JA; Flynn PM J Infect Dis; 2011 Nov; 204(10):1475-82. PubMed ID: 21949042 [TBL] [Abstract][Full Text] [Related]
17. Report of the 6th meeting on the evaluation of pandemic influenza vaccines in clinical trials World Health Organization, Geneva, Switzerland, 17-18 February 2010. Girard MP; Katz J; Pervikov Y; Palkonyay L; Kieny MP Vaccine; 2010 Oct; 28(42):6811-20. PubMed ID: 20659520 [TBL] [Abstract][Full Text] [Related]
18. WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: supporting developing country production capacity through technology transfer. Friede M; Palkonyay L; Alfonso C; Pervikov Y; Torelli G; Wood D; Kieny MP Vaccine; 2011 Jul; 29 Suppl 1():A2-7. PubMed ID: 21684422 [TBL] [Abstract][Full Text] [Related]